Featuring an interview with Dr Shannon N Westin, including the following topics:

• Biomarker testing and utility in ovarian cancer (OC) (0:00)
• Selection of a PARP inhibitor for the treatment of OC (9:18)
• Addition of immunotherapy to up-front treatment of OC (15:50)
• Utility of minimal residual disease and circulating tumor DNA assays in OC (17:10)
• Selection of treatment for recurrent OC (21:46)
• Clinical decision-making involved with PARP inhibitors for endometrial cancer (EC) (28:22)
• Adjuvant therapy for EC (32:28)
• Utility of lenvatinib/pembrolizumab in EC (35:08)
• Clinical findings supporting the potential use of selinexor for EC (39:42)
• Key findings involving trastuzumab deruxtecan (T-DXd) for HER2-positive gynecologic cancers (43:22)
• Management of adverse effects associated with T-DXd (49:49)

CME information and select publications